Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
about
Confronting the Care Delivery Challenges Arising from Precision MedicineIntegrating next-generation sequencing into clinical oncology: strategies, promises and pitfallsRationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisMolecular predictive markers in tumors of the gastrointestinal tractDynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology.Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean InstitutionDetection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assayGenomics of gallbladder cancer: the case for biomarker-driven clinical trial design.An appraisal of drug development timelines in the Era of precision oncology.Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.Targeted therapies: What have we learned from SHIVA?Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.Debunking the Delusion That Precision Oncology Is an Illusion.Personalized cancer therapy: leveraging a knowledge base for clinical decision-making.The evidence framework for precision cancer medicine.Challenging Standard-of-Care Paradigms in the Precision Oncology Era.Targeted therapy in endometrial cancer: Making progress.Next Generation Sequencing in metastatic castrate-resistant prostate cancer.Value-based genomics.Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8-9 February 2018.Precision oncology: separating the wheat from the chaff
P2860
Q26747282-DD3EE98E-F06A-479A-AB4B-B3303A3D5B10Q28066709-25666726-336B-4DAB-98E6-BB63E9587A78Q28069975-D8334356-20D2-462E-9CEA-35C648F2B4C6Q28070583-8AA19BC1-AC37-4457-877B-D3E1A11BC604Q33756769-ECF51847-D879-43F5-B3A4-53AAEA55A221Q35997083-B07786E5-2BD1-4F1F-AA24-72678420C577Q36962764-0D5E34A7-CF53-4E04-AF5E-DA37911D4C3FQ37017110-C0E2CBE6-2F62-4E1D-AE1D-056B44FA63B6Q37619700-669EC9FD-C73E-4CC7-ABFC-540279C897B4Q38679628-A55A102F-9299-451A-A7F3-BEB18EB3EA6DQ38996431-20C91256-846C-4003-B011-D4D3307F0FD0Q42381429-72E400E9-E93D-4862-8276-4FBB1647F63FQ43933795-81F2AB35-3755-4224-8495-748270B85894Q46182953-67EDBABB-6EDF-4703-A9FF-B8F822C39B5DQ46296816-0EEFE7E5-1D2C-4FE1-A6FE-E8C3E172396DQ46539715-543EF414-D29D-4694-AFCA-B88E62A03D89Q47199187-55FF8F7A-7AF1-4FD2-B40E-4E38C74B5BA1Q49644220-542C9CAF-F1F9-4DDD-8C07-5E0BB4DF69FFQ49835188-62DDDB19-1A70-4DFD-AE19-A7019A8D39FFQ54171730-8DA49CA2-69CE-488D-9EAC-DFF46F2A4A7EQ55244223-BB5E51FE-A616-4BEA-B3D3-FC52C98EB889Q55339672-CCE96BAA-97B0-4C9E-8157-850B00BC9013Q55395455-E9766DAE-96DF-4CAA-9B79-646F5C471E12Q58698377-1C7B0BE7-4264-474D-8164-8475E6F65F03
P2860
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Impact of a Biomarker-Based St ...... Trials Leading to FDA Approval
@en
type
label
Impact of a Biomarker-Based St ...... Trials Leading to FDA Approval
@en
prefLabel
Impact of a Biomarker-Based St ...... Trials Leading to FDA Approval
@en
P2093
P2860
P50
P356
P1476
Impact of a Biomarker-Based St ...... Trials Leading to FDA Approval
@en
P2093
Alexander M Eggermont
Caimiao Wei
David S Hong
Denis L Jardim
J Jack Lee
John Mendelsohn
Richard L Schilsky
Vladimir Lazar
P2860
P356
10.1093/JNCI/DJV253
P407
P577
2015-09-15T00:00:00Z